-
Injection consistency evaluation TOP10: Yangtze River, Kelun, Qilu lead
Time of Update: 2022-09-21
Just into September, more than 10 injections (in terms of drug name + group) have passed or are deemed to have passed the consistency evaluation. According to the data of the Intranet, the current ev
-
The price of sour jujube kernels has risen by more than 1,000 yuan, is it a curse caused by artificial speculation?
Time of Update: 2022-09-21
Hebei sour jujube kernel dealers introduced that the local production has entered the middle stage, there have not been a large number of new goods into the market, the price of sour jujube fresh goods rose from 13 yuan on August 15 to the current 20 yuan, resulting in a large increase in farmers' enthusiasm for harvesting.
-
Jiangsu: Psychological treatment programs have been included in basic medical insurance since October
Time of Update: 2022-09-21
The reporter learned from the recent meeting of the Jiangsu Provincial People's Congress Standing Committee on the key handling of the deputies' suggestions on medical security that the Jiangsu Provi
-
Under the change of the pharmaceutical environment, a large number of multinational pharmaceutical companies will accelerate the "change of coach" in 2022!
Time of Update: 2022-09-21
AstraZeneca: Ming Liu takes over as Vice President of AstraZeneca China AstraZeneca: Ming Liu takes over as Vice President of AstraZeneca China On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of AstraZeneca China, head of the Lung Cancer Treatment and Tumor Immunotherapy Related Areas of the Oncology Division, and joined the China management team to report directly to Chen Kangwei, General Manager of AstraZeneca Oncology Division, effective August 30.
-
Chinese medicine is also welcoming good news, "going to sea" will be accelerated!
Time of Update: 2022-09-21
19 billion US dollars; the State Administration of Traditional Chinese Medicine has supported domestic TCM institutions to build 30 high-quality TCM overseas centers in the "Belt and Road" countries, and 56 TCM international cooperation bases in China, providing high-quality TCM services for the people of the "Belt and Road" countries.
-
Sinopharm's performance reached a new high Sinopharm Shares, Tai Chi... Strategic layout exposure
Time of Update: 2022-09-21
On September 6, the list of the top 500 Chinese enterprises in 2022 was announced, and Sinopharm Group ranked 28th. In recent years, Sinopharm Group's revenue has repeatedly reached new highs, breaki
-
Recently, the field of diabetes has ushered in a number of blockbuster new drugs
Time of Update: 2022-09-21
According to the China Drug Clinical Trial Registration and Information Publicity Platform, Eli Lilly has conducted five related clinical trials in China, in addition to the completed clinical trial of type 2 diabetes, there are three ongoing international multicenter Phase 3 clinical trials, the indications are obstructive sleep apnea and obesity, overweight/obesity, and reducing the compound outcomes of major adverse cardiovascular events in patients with type 2 diabetes mellitus with an increased risk of cardiovascular disease.
-
The pharmaceutical company's current personnel "earthquake": the president resigned, and the CEO of the subsidiary changed
Time of Update: 2022-09-21
Previously, the combination therapy of "amphavir monoclonal antibody" and "romizumab" of Tengsheng Bo Pharmaceuticals has received high attention, and since the drug was approved for listing at the end of last year, the company announced the commercialization of the product in China in July 2022, and the price is expected to be within 10,000 yuan.
-
Hainan: Tax, medical insurance and social security to achieve "one window through the office"
Time of Update: 2022-09-21
The relevant person in charge of the Hainan Provincial Taxation Bureau said that the "one-window general office" will effectively solve the "pain points" such as multi-window handling, repeated consultation, and long processing time of payers, marking a new level in the handling mode of social security management and payment business in Hainan Province.
-
Notice on publicly soliciting opinions on the "Technical Guidelines for the Continuous Manufacture of Oral Solid Preparations of Chemical Drugs (Draft for Solicitation of Comments)"
Time of Update: 2022-09-20
Drug Evaluation Center of the State Drug Administration September 9, 2022 In order to encourage innovation and pharmaceutical modernization, help the implementation of the ICH Q13 guiding principles in China, and also to guide the research and development of enterprises and unify the evaluation scales, our center organized the drafting of the "Technical Guidelines for continuous manufacturing of oral solid preparations of chemical drugs (Draft for Comments)", which is now soliciting opinions from all sectors of society.
-
With the empowerment of science and technology, pharmaceutical companies are accelerating the exploration of new paths for digital transformation
Time of Update: 2022-09-20
In general, with the help of digital transformation, it can help pharmaceutical companies achieve refined operation, improve production efficiency, improve drug quality, and bring new growth breakthrough points to pharmaceutical companies.
-
Pharmaceutical companies are accelerating the "grab" of more than one billion yuan of heavy spiritual medicine market!
Time of Update: 2022-09-20
Recently, Fosun Pharma announced that the drug registration application of aripiprazole oral solution developed by its holding subsidiary Fosun Pharmaceutical Industry and its holding subsidiary Jinzhou Aohong Pharmaceutical has been accepted by the State Food and Drug Administration for the treatment of schizophrenia in adults and adolescents over 15 years old.
-
Sugar reduction and re-star Tirzepatide reported production in China, and sales are expected to exceed 10 billion US dollars in 2030
Time of Update: 2022-09-20
In the treatment of type 2 diabetes, in January this year, Eli Lilly announced that Tirzepatide had reached the primary and all key secondary endpoints in a 40-week SURPASS-AP clinical trial (comparing Tirzepatide with dose-titrated insulin glargine), significantly reducing glycosylated hemoglobin and body weight in patients with type 2 diabetes.
-
The key is to turn a profit from a profit and reduce the cost of raw materials such as Epimedium!
Time of Update: 2022-09-20
In terms of products, in the first half of 2022, in the company's main business, the operating income of traditional Chinese medicine was 340 million yuan, an increase of 50.
-
Shanghai pharmaceutical companies have accelerated the pace of "going to sea" and competed with foreign enterprises in a differentiated manner
Time of Update: 2022-09-20
In addition, the author has learned that Shanghai Jiyu Pharmaceutical, a subsidiary of Jimin Trust Group, has recently reached an exclusive licensing agreement with Roche and its Genentech, in which Shanghai Jiyu exclusively licenses the development and commercialization rights of the oral androgen receptor (AR) degrader JMKX002992 with independent intellectual property rights to Genentech in the world.
-
The operating area is not less than 100㎡! Is it getting harder and harder to apply for a designated pharmacy?
Time of Update: 2022-09-20
01 Henan Medical Insurance Bureau: "Non-medical insurance card" area is less than 20% The "Plan" divides the assessment work of designated pharmacies into two forms of assessment, written and on-site, covering a total of 9 types of inspection items, involving whether the written materials are consistent with the actual situation, practicing pharmacist qualification certificates and labor contracts, and drug purchase, sale and inventory management.
-
Notice of Public Solicitation of Recommendations for the Implementation of the ICH Q3D(R2): Guiding Principles on Elemental Impurities and Chinese Edition
Time of Update: 2022-09-20
Q3D (R2) English version Drug Evaluation Center of the State Drug Administration September 8, 2022 In order to promote the smooth implementation of the newly revised ICH guidelines in China, our center has formulated the implementation recommendations of "Q3D (R2): Guiding Principles for Elemental Impurities" and organized the translation of Chinese version.
-
The development of the out-of-hospital market has become the focus of the development of pharmaceutical companies and circulation enterprises!
Time of Update: 2022-09-20
In recent years, with the continuous implementation of medical reform measures such as medical insurance cost control, centralized procurement, zero addition of drugs in hospitals, and outflow of prescriptions, the original domestic pharmaceutical circulation pattern has been broken, and the layout has become the consensus of pharmaceutical companies in the off-hospital market.
-
The development of new drugs has accelerated, and recent clinical trials of many drugs have ushered in new progress
Time of Update: 2022-09-20
The clinical trial of BUCHANG Pharmaceutical BC008-1A injection drug was approved Recently, Buchang Pharmaceutical announced that its subsidiary has obtained a notice of approval for clinical trials of BC008-1A injection drugs, and the main indication of the drug is advanced solid tumor.
-
70% of the company's revenue growth, the CRO under the capital winter is really prosperous?
Time of Update: 2022-09-20
Essence: Prosperity is only an illusion, and performance lag is the key For the CRO industry, people have always had the impression of being a "water seller", who can still achieve objective operating income without taking the risks brought by innovative drugs, which may not be obvious in the strong period of medicine, but it is vividly reflected in today's increasingly severe "biological significance winter".
